• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Cadrenal Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    4/17/25 6:12:02 AM ET
    $CVKD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CVKD alert in real time by email
    false 0001937993 0001937993 2025-04-17 2025-04-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (date of earliest event reported): April 17, 2025

     

    Cadrenal Therapeutics, Inc.

    (Exact name of registrant as specified in charter)

     

    Delaware   001-41596   88-0860746
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)   (IRS Employer
    Identification No.)

     

    822 A1A North, Suite 306

    Ponte Vedra, Florida 32082

    (Address of principal executive offices and zip code)

     

    (904) 300-0701

    (Registrant’s telephone number including area code)

     

    N/A

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbols   Name of each exchange on which registered
    Common Stock, par value $0.001 per share   CVKD  

    The Nasdaq Stock Market LLC

    (Nasdaq Capital Market)

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

      

    Item 8.01. Other Events.

     

    On April 17, 2025, Cadrenal Therapeutics, Inc., a Delaware corporation, (the “Company”), filed a prospectus supplement (the “Prospectus Supplement”) with the U.S. Securities and Exchange Commission (the “SEC”) in connection with the Company’s “at the market offering” program for the offer and sale of up to $2,169,272 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), from time to time through H.C. Wainwright & Co., LLC (“Wainwright”), as sales agent, pursuant to the Company’s existing At the Market Offering Agreement (the “ATM Agreement”), dated March 11, 2024. As of the date hereof, the Company has sold an aggregate of $7,655,240 of shares of Common Stock pursuant to the ATM Agreement.

     

    The offer and sale of up to $2,169,272 shares of Common Stock by the Company under the ATM Agreement is made pursuant to the Company’s registration statement on Form S-3 (File No. 333-277835), initially filed with the SEC on March 12, 2024 and declared effective by the SEC on March 20, 2024 (the “Registration Statement”), and the Prospectus Supplement.

     

    Under the ATM Agreement, the Company will set the parameters for the sale of shares, including the number of shares to be issued, the time period during which sales are requested to be made, limitation on the number of shares that may be sold in any one trading day and any minimum price below which sales may not be made. Subject to the terms and conditions of the ATM Agreement, Wainwright may sell the shares by methods deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended. Wainwright will use commercially reasonable efforts in conducting such sales activities consistent with its normal trading and sales practices, and applicable state and federal laws. The ATM Agreement may be terminated by the Company upon written notice to Wainwright, as specified in the ATM Agreement for any reason or by Wainwright upon written notice to the Company for any reason or at any time under certain circumstances, including but not limited to the occurrence of a material adverse change in the Company.

     

    The ATM Agreement provides that Wainwright will be entitled to compensation for its services of 3.0% of the gross sales price of all shares sold through Wainwright under the ATM Agreement. The Company has no obligation to sell any shares under the ATM Agreement, and may at any time suspend solicitation and offers under the ATM Agreement. The ATM Agreement contains customary representations, warranties and agreements by the Company, indemnification obligations of the Company and Wainwright, other obligations of the parties and termination provisions.

     

    Blank Rome LLP, counsel to the Company, has issued a legal opinion relating to the validity of the $2,169,272 shares of Common Stock that may be offered and sold pursuant to the ATM Agreement and related Prospectus Supplement. A copy of such legal opinion, including the consent included therein, is attached as Exhibit 5.1 to this Current Report on Form 8-K.

     

    The foregoing description of the ATM Agreement is not complete and is qualified in its entirety by reference to the full text of such agreement, a copy of which is incorporated herein by reference as Exhibit 1.1 to this Current Report on Form 8-K.

     

    This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the shares of Common Stock discussed herein, nor shall there be any sale of such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits

     

    The following exhibits are furnished with this Current Report on Form 8-K:

     

    Exhibit
    Number
      Exhibit Description
    1.1   At the Market Offering Agreement by and between Cadrenal Therapeutics, Inc. and H.C. Wainwright & Co., LLC (incorporated by reference as Exhibit 1.1 to the Current Report on Form 8-K filed on March 12, 2024)
    5.1   Opinion of Blank Rome LLP
    23.1   Consent of Blank Rome LLP (included in Exhibit 5.1)
    104   Cover Page Interactive Data File (the cover page XBRL tags are embedded within in the inline XBRL document)

     

    1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Dated: April 17, 2025 CADRENAL THERAPEUTICS, INC.
       
      By: /s/ Quang X. Pham
      Name: Quang X. Pham
      Title: Chairman and Chief Executive Officer

     

    2

     

     

    Get the next $CVKD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CVKD

    DatePrice TargetRatingAnalyst
    12/18/2023$4.00Outperform
    Noble Capital Markets
    More analyst ratings

    $CVKD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update

      Leadership appointment strengthens strategic and development capabilities FDA Type D Meeting provides additional guidance for advancing the clinical development of tecarfarin Collaboration Agreement with Abbott (NYSE:ABT) validates the need for new anticoagulation options Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing therapeutics for patients with cardiovascular disease, today reported its financial results for the first quarter ended March 31, 2025, and provided an update on the strategic focus of the company and clinical development of tecarfarin. "In the first quarter of 2025, Cadrenal continued to build on the momentum we achieved during 2024," sa

      5/8/25 8:00:00 AM ET
      $ABT
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cadrenal Therapeutics to Present at Inaugural Centri Capital Conference at Nasdaq

      Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a late-stage biopharmaceutical company focused on the development of tecarfarin, a new Phase 3-ready oral vitamin K antagonist anticoagulant, today announced that Chairman and CEO Quang X. Pham will present at the inaugural Centri Capital Conference, to be held at Nasdaq in New York City on April 22, 2025. Mr. Pham will deliver a company overview and provide updates on the development of tecarfarin, Cadrenal's lead asset, addressing unmet needs in anticoagulation therapy. The Centri Capital Conference will feature attendees from across the capital markets and investment community, connecting with executives from companies shaping the future of he

      4/17/25 9:40:00 AM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences

      Management Available for One-to-One Meetings Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a late-stage biopharmaceutical company focused on the development of tecarfarin, a new Phase 3-ready oral vitamin K antagonist anticoagulant, today announced its participation in a series of high-profile conferences throughout the second quarter of 2025, underscoring the Company's commitment to advancing innovation and clinical development in anticoagulation therapy. Chief Operating Officer, Jeff Cole and Chief Medical Officer, Dr. James Ferguson will represent the Company at the 18th National Conference on Anticoagulation Therapy in Washington, D.C. from April 3-5, engaging with leading experts and ke

      4/3/25 8:00:00 AM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CVKD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Noble Capital Markets initiated coverage on Cadrenal Therapeutics with a new price target

      Noble Capital Markets initiated coverage of Cadrenal Therapeutics with a rating of Outperform and set a new price target of $4.00

      12/18/23 8:12:12 AM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CVKD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Cadrenal Therapeutics Inc.

      SC 13G/A - Cadrenal Therapeutics, Inc. (0001937993) (Subject)

      11/14/24 4:00:17 PM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Cadrenal Therapeutics Inc.

      SC 13G - Cadrenal Therapeutics, Inc. (0001937993) (Subject)

      10/4/24 4:15:02 PM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CVKD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form 4 filed by CEO and Chairman Pham Quang X

      4/A - Cadrenal Therapeutics, Inc. (0001937993) (Issuer)

      3/24/25 8:38:14 PM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Ferguson James J. Iii

      4 - Cadrenal Therapeutics, Inc. (0001937993) (Issuer)

      2/6/25 4:51:35 PM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Ferguson James J. Iii

      3 - Cadrenal Therapeutics, Inc. (0001937993) (Issuer)

      2/6/25 4:50:29 PM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CVKD
    SEC Filings

    See more
    • Cadrenal Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Cadrenal Therapeutics, Inc. (0001937993) (Filer)

      5/8/25 4:05:33 PM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Cadrenal Therapeutics Inc.

      10-Q - Cadrenal Therapeutics, Inc. (0001937993) (Filer)

      5/8/25 6:17:43 AM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cadrenal Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Cadrenal Therapeutics, Inc. (0001937993) (Filer)

      4/17/25 6:12:02 AM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CVKD
    Leadership Updates

    Live Leadership Updates

    See more
    • Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin

      James J. Ferguson, MD, FACC, FAHA, joins as Chief Medical Officer Extensive experience provides strong support for advancing specialized cardiovascular assets, including leading the late-stage clinical development of tecarfarin and other business development opportunities Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapies, with the late-stage asset tecarfarin, a new Vitamin K antagonist, today announced a leadership transition appointing James J. Ferguson, MD, FACC, FAHA, as its new Chief Medical Officer, effective immediately. Dr. Ferguson is a distinguished medical expert with over 25

      2/6/25 9:00:00 AM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings

      Lays out Phase 3 Clinical and Regulatory Path for Tecarfarin and Three-Year Strategic Plan Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), announced today its engagement in three key events leading up to and during the 43rd Annual J.P. Morgan Healthcare Conference Week, to be held on January 13-16, 2025 in San Francisco, California. Cadrenal Therapeutics is a biopharmaceutical company focused on developing tecarfarin, a novel oral vitamin K antagonist (VKA) in advanced clinical development and designed to be a superior and safer chronic anticoagulant therapeutic for warfarin-dependent patients with implanted cardiac devices or rare cardiovascular conditions. Quang X. Pham, Chairman and Chief

      12/18/24 9:00:00 AM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial

      PONTE VEDRA, Fla., Feb. 8, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing tecarfarin, a novel Vitamin K Antagonist (VKA) for unmet needs in anticoagulation (blood thinning) therapy, today announced the appointment of Jeff Cole to the newly created position of Chief Operating Officer. In this role, Mr. Cole will be responsible for the Company's manufacturing and supply chain operations, intellectual property, commercialization strategies, and supporting partnering activities for tecarfarin. Mr. Cole brings over 25 years of

      2/8/24 9:00:00 AM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CVKD
    Financials

    Live finance-specific insights

    See more
    • Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin

      Recent Collaboration Agreement with Abbott Global Enterprises Limited ("Abbott") in support of Phase 3 randomized, multicenter study, entitled TECH-LVAD Recent FDA Type D Meeting provides additional guidance for advancing clinical development of tecarfarin Leadership appointments to strengthen development capabilities Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company focused on the development of tecarfarin, a new Phase 3 ready oral vitamin K antagonist, today reported full year results for the period ended December 31, 2024, and provided a business update and highlights of the path forward for the clinical advancement of tecarfarin. "2024 for Cadrenal was a year of

      3/13/25 4:05:00 PM ET
      $ABT
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care